Amgen Non-GAAP EPS of $3.98 in-line, revenue of $6.1B misses by $140M
Amgen press release (NASDAQ:AMGN): Q1 Non-GAAP EPS of $3.98 in-line.
Revenue of $6.1B (-2.2% Y/Y)  misses by $140M.
Product sales growth was driven by 14% volume growth, partially offset by 5% lower net selling price, 3% unfavorable changes to estimated sales deductions, 2% lower inventory levels and 2% negative impact from foreign exchange.

2023 Guidance
Total revenues in the range of $26.2 billion to $27.3 billion vs. $26.72B consensus
On a GAAP basis, EPS in the range of $15.38 to $16.59, and a tax rate in the range of 17.0% to 18.5%.
On a non-GAAP basis, EPS in the range of $17.60 to $18.70 vs. $17.83 consensus, and a tax rate in the range of 18.0% to 19.0%.
Capital expenditures to be approximately $925 million.